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Abstract 23 
Objective: The effect of cinnamon (Cinnamomum Zeylanicum) on serum 24 
C-reactive protein (CRP), an acute phase protein commonly used as a 25 
marker of inflammation, is uncertain. Therefore, the objective of the 26 
present study was to conduct a systematic review and meta-analysis of 27 
published randomised controlled trials (RCTs) of cinnamon to determine 28 
the effect on levels of serum CRP, relative to controls.  29 
Design: Studies were identified by a search of electronic databases 30 
including PubMed, Cochrane Library, Google Scholar and Scopus before 31 
August 2018. Combined and stratified analyses were used. Weighted 32 
mean differences (WMD) and its 95% confidence interval were estimated 33 
for net change in serum CRP by using random-effects model. The 34 
heterogeneity of meta-analysis was assessed by χ2 and I2 test. 35 
Results: Six studies were identified, and data from 285 participants were 36 
included. Pooled analysis showed significant reductions in serum CRP 37 
(WMD: −0.81 mg/L, 95% CI: −1.36 to -0.26, p=0.004), with significant 38 
heterogeneity between selected studies. Improvements in sub-group 39 
analysis were observed when baseline CRP levels were greater than 3 40 
mg/dL, and in trials of >12 weeks duration. Doses <1500 mg/day and 41 
≥1500 mg/day were effective in lowering serum CRP (WMD: −0.56 42 
mg/dL, 95% CI: −1.01 to -0.10, p=0.02 and WMD: −2.13 mg/dL, 95% 43 
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CI: −4.08 to -0.19, p=0.03), respectively, with significantly reduced 44 
heterogeneity in trials with lower doses of cinnamon <1500 mg/day (test 45 
for heterogeneity: P=0.22 and I2= 33%). No changes were found in 46 
controls. 47 
Conclusion: Cinnamon supplementation improves levels of serum CRP, 48 
particularly in chronic conditions where basal CRP levels are raised. 49 
Key-words: Anti-inflammatory; Cinnamon; CRP; meta-analysis; RCT. 50 
 51 
52 
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Introduction. 53 
Cinnamon (Cinnamomum Zeylanicum) belongs to the genus 54 
Cinnamomum of the Lauraceaeis family, derived from the Hebraic and 55 
Arabic term amomon, meaning fragrant spice plant. Comprising over 300 56 
species, it is widely used for its culinary and medicinal properties with 57 
Ceylon and Cassia cinnamon being the most abundant in the U.S and EU 58 
markets1-3.  Cinnamon has attracted much attention due to their putative 59 
health-related properties, which have been ascribed in part to their 60 
polyphenolic content; a diverse group of secondary plant metabolites 61 
classified as phenolic acids, flavonoids, stilbenes and lignans4. Evidence 62 
from experimental studies have shown anti-inflammatory and 63 
antioxidative properties, particularly in their ability to reduce reactive 64 
oxygen species (ROS), and improve insulin sensitivity and carbohydrate 65 
metabolism 5-8. Clinical studies also indicate improvement in 66 
anthropometric parameters, inflammatory mediators, glycemic indices 67 
and lipid profiles in patients with type-2 diabetes mellitus (T2DM), 68 
nonalcoholic fatty liver disease and rheumatoid arthritis, and those with a 69 
BMI ≥ 27 kg/m2, following cinnamon supplementation 9.  70 
C-reactive protein (CRP) is an acute phase protein commonly used as a 71 
marker of inflammation, and is associated with early stages of several 72 
chronic conditions including coronary artery disease (CAD), T2DM, 73 
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rheumatoid arthritis, pre-diabetes, obesity and nonalcoholic fatty liver 74 
disease 10-12. This increases greatly in inflammation processes and shows 75 
specific responses in medical conditions such as polycythemia, anemia, 76 
and congestive heart failure with no significant changes. However, 77 
compared to conventional assessments of inflammation factors such as 78 
erythrocyte sedimentation rate (ESR) test, CRP assessment is an ideal 79 
indicator in inflammations 10-13. Effects of cinnamon supplementation on 80 
serum CRP level have been investigated in clinical trial studies. However, 81 
evidence from RCTs are limited and remain inconclusive. Therefore, the 82 
aim of the present study was to conduct a systematic review and meta-83 
analysis to assess the efficacy of cinnamon supplementation on serum 84 
CRP in several chronic inflammatory conditions.  85 
Methods and Materials. 86 
The present meta-analysis was conducted in accordance with PRISMA 87 
(Preferred Reporting Items for Systematic reviews and Meta-Analysis) 88 
requirements for interventional research 14. 89 
 90 
Search Strategy 91 
Four databases, including Pubmed™, Cochrane Library™, Google 92 
Scholar™ and Scopus™ were used to identify related publications. 93 
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Published RCTs were searched from inception to August 2018. Reference 94 
lists from retrieved studies were also manually searched for additional 95 
relevant publications. The following searches in titles, abstracts and 96 
keywords: “CRP or C reactive protein” in combination with “cinnamon” 97 
was performed. Studies were included if they followed a RCT study 98 
design with cinnamon supplementation as the intervention. Those 99 
published in English and/or Persian were included in the study. 100 
Inclusion and exclusion criteria 101 
The inclusion criteria for selected studies were based on the following; 102 
RCTs of oral cinnamon supplementation, those with a duration of more 103 
than one week and those reporting mean or median values of serum CRP 104 
levels at baseline and by the end of supplementation in control and 105 
intervention groups with SD, SEM or 95% CI. The exclusion criteria 106 
included duplicated studies, those with no control or placebo group, those 107 
with insufficient data at baseline and/or final levels of serum CRP in 108 
control and treatment groups, studies with case-control, cohort or cross-109 
sectional design, in vitro and animal studies. 110 
Data extraction 111 
Data were extracted from published studies independently by three 112 
reviewers, and any disagreements were resolved by consensus among the 113 
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researchers using the standardised extraction forms to guarantee accuracy 114 
and consistency. The following key data were extracted: year of 115 
publication, country where the intervention was conducted, sample size of 116 
both intervention and control groups, clinical condition of subjects, 117 
intervention/placebo details and composition including the dosage of 118 
cinnamon supplementation (gram or mg per day), treatment duration and 119 
significant outcomes. In addition, serum levels of CRP were reported as 120 
mg/dL. For papers containing data in mmol/l, a numerical conversion to 121 
mg/dL was carried out based on molecular weight. Corresponding authors 122 
of trials with no reported mean and SD values for any outcomes of 123 
interest were contacted to request their data. Only the studies providing 124 
these data were included in the present meta-analysis 15. 125 
Quality assessment 126 
We performed a systematic assessment of bias in the included study by 127 
using the Cochrane criteria16.   The items used for each included study 128 
assessment were the following ones: adequacy of sequence generation, 129 
the  allocation  concealment, blinding of participants, personnel and 130 
outcome assessment, the  addressing of  drop-outs  and  incomplete  131 
outcome  data, selective outcome reporting and other potential sources of 132 
bias.  According to the recommendations of the Cochrane Handbook, the 133 
included studies were rated  on  each  of  the  items  as ‘L’  indicating  a  134 
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low  risk  of  bias,  ‘h’ indicating  a  high  risk  of  bias  or  ‘u’  when  the  135 
risk  of  bias  was unclear16. 136 
Statistical analysis 137 
The statistical analyses were performed using Review Manager Software 138 
(RevMan 5.3; Cochrane Collaboration, Oxford, England) and 139 
Comprehensive Meta-Analysis (version 3.2; Biostat). The pooled 140 
weighted mean difference (WMD) and its 95% confidence interval (CI) 141 
were estimated to assess the effects of cinnamon on levels of serum CRP. 142 
The mean and standard deviation (SD) of levels of serum CRP at baseline 143 
and after supplementation in both intervention and control groups were 144 
used. Based on the method of Hozo et al. all reported median values with 145 
their confidence intervals (CI) or their ranges were converted to mean and 146 
SD17.  Existence of heterogeneity and the percentage of total variation 147 
between studies was assessed by the Cochran’s Q-test at P < 0.05 level of 148 
significance and I2 test (I2< 50%). Based on the results (present 149 
significant heterogeneity with p<0.05 from χ2 test), a random effects 150 
model was used if I2 > 50% and P<0.1. A fixed effects model was used if 151 
I2 < 50% and P>0.1.To identify the influence of modulators, pre-defined 152 
subgroup analyses were conducted according to the Cochrane guidelines 153 
including treatment duration, dose of intervention, measuring serum 154 
CRP/hs-CRP and baseline CRP level. Sensitivity analysis was performed 155 
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to estimate the effects of each trial on the pooled effect size, in which a 156 
single trial was omitted each time and the effect size was re-calculated to 157 
assess the influence on the overall effect size. In order to examine 158 
potential publication bias, the funnel plot test was performed. If 159 
publication bias exists, the funnel plot shows an asymmetric shape. 160 
Additionally, Begg’s rank correlation test and Egger’s weighted 161 
regression test were used to elucidate possible bias. A P-value <0.05 was 162 
considered statistically significant.  163 
 164 
Results. 165 
Search results and study selection 166 
A flow chart depicting the process of selection and literature search is 167 
presented in Figure 1. The literature search of electronic databases 168 
identified 205 potential relevant articles. After removing duplicates 169 
(n=112), titles and abstracts were screened and sixty-four studies were 170 
excluded, as they were not relevant to our analysis or were not in English 171 
language. A further 23 studies were excluded after further evaluation due 172 
to molecular or animal experiments (n=11), observational studies (n=2), 173 
reviews or editorial papers (n=5), not enough data for characterisation of 174 
subjects or insufficient reporting of baseline and/or follow-up serum CRP 175 
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levels in the cinnamon and/or control group (n=2), and studies with no 176 
control group (n=3). Finally, a total of 6 RCTs were included in this 177 
meta-analysis.  178 
Description of the studies 179 
All trials were published between 2014 to 2018 and were conducted in 180 
France, India, Iran and the USA 18-23. A total of 285 adult participants 181 
were re-analysed in the study, of which 144 were allocated to receive 182 
cinnamon supplementation and 141 to a control group. Cinnamon dosage 183 
ranged from 1200 mg/day to 3000 mg/day, with a median dose of 1850 184 
mg/day 18-23. Cinnamon capsules, stick and extracts were the formulations 185 
used in these trials.  Duration of supplementation ranged from 8 weeks to 186 
24 weeks with a median duration of 14 weeks 18-23. Selected studies 187 
enrolled patients with non-alcoholic fatty liver disease, T2DM, metabolic 188 
syndrome, obesity, pre-diabetes and rheumatoid arthritis 18-23. 189 
Baseline level of serum CRP ranged from 1.69 mg/dL to 5.74 mg/dL with 190 
a median level of 3.76 mg/dL in the intervention and 3.75 mg/dL in the 191 
control groups, respectively. Five of the 6 studies were conducted in both 192 
males and females, with one study conducted only in female participants 193 
18-23. All included trials followed a parallel study design. Three trials 194 
evaluated cinnamon in combination with black tea, L-carnosine plus 195 
chromium guanylate and a multiple dietary supplement containing 196 
11 
 
cinnamon powder 19, 22, 23 (Table 1). Cinnamon supplementation was 197 
apparently safe and well tolerated by participants in all of the included 198 
studies, and no adverse effects were reported.  199 
Risk of bias assessment 200 
An  unclear  risk  of  bias was observed in some  of  the  items  including  201 
allocation  concealment and other potential sources of bias. However, 202 
most of the included studies were characterized by adequate information 203 
regarding sequence generation, allocation concealment and blinding of 204 
participants and personnel. The incomplete outcome data and selective 205 
outcome reporting showed a low risk of bias. Details of the quality of bias 206 
assessment are presented in Table 2.  207 
Pooled estimate of the effect of cinnamon supplementation on serum CRP  208 
Significant reductions in the levels of serum CRP were observed 209 
following cinnamon supplementation in 3 studies 20, 22, 23. Weighted mean 210 
difference (WMD) of studies with random effects model analysis showed 211 
a significant improvement in serum CRP (WMD: −0.81 mg/L, 95% CI: 212 
−1.36 to -0.26, p=0.004) with a significant heterogeneity between the 213 
included trials (test for heterogeneity: P < 0.0002 and I2= 79%)(Figure 214 
2).  215 
Subgroup analyses 216 
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Subgroup analysis was performed to determine the potential source of 217 
heterogeneity, based on study duration, cinnamon dose, serum CRP 218 
and/or high sensitivity CRP (hs-CRP) and baseline CRP following 219 
supplementation (Table 3). Results showed that cinnamon 220 
supplementation significantly reduced serum CRP levels in participants 221 
when the duration of the study was >12 weeks (WMD: −0.42 mg/L, 95% 222 
CI: −0.65 to -0.20, p=0.0002). The heterogeneity significantly decreased 223 
after subgroup analysis by duration of study (test for heterogeneity: P = 224 
0.96 and I2= 0%). Subgroup analysis on studies with cinnamon doses of 225 
<1500 mg/day and ≥1500 mg/day also significantly influenced levels of 226 
serum CRP (WMD: −0.56 mg/dL, 95% CI: −1.01 to -0.10, p=0.02 and 227 
WMD: −2.13 mg/dL, 95% CI: −4.08 to -0.19, p=0.03), respectively. 228 
There was significantly reduced heterogeneity in studies with lower doses 229 
of cinnamon supplementation (test for heterogeneity: P=0.22 and I2= 230 
33%). Results of subgroup analysis based on baseline serum CRP also 231 
showed that cinnamon supplementation decreased levels of CRP in those 232 
with baseline CRP levels of more than 3 mg/dL (WMD: −0.42 mg/L, 233 
95% CI: −0.65 to -0.20, p=0.0002). Moreover, the heterogeneity 234 
decreased significantly after subgroup analysis by trials with baseline 235 
CRP levels of more than 3 mg/dL.  236 
Sensitivity analysis 237 
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Sensitivity analysis was performed to determine the effect of each study 238 
on the estimated pooled effect size. Results of omitting each study on the 239 
effect size ranged from -0.55 mg/L (95% CI=-0.98, -0.11) to -1.07 mg/L 240 
(95% CI=-1.80,-0.35)(Figure 3). 241 
Publication bias 242 
The publication bias of this meta-analysis was assessed by examination of 243 
funnel plot. The symmetrical funnel plots suggested that the selection of 244 
publication was not a possible source of bias (Figure 4). The absence of 245 
publication bias was confirmed by Egger’s linear regression (intercept: -246 
3.9; standard error: 3.82; 95% CI: -5.91, 1.94; t= 1.4, df=4; two-tailed 247 
p=0.23). Moreover, Begg’s rank correlation did not highlight any 248 
publication bias (Kendall’s Tau with continuity correction:-0.4; z=1.12; 249 
two-tailed p=0.25).  250 
 251 
Discussion 252 
The present meta-analysis included a total of 285 adults presenting with 253 
non-alcoholic fatty liver disease, T2DM, metabolic syndrome, obesity, 254 
pre-diabetes and rheumatoid arthritis from 6 RCTs. Despite considerable 255 
heterogeneity among the studies, our findings indicate improvement in 256 
the levels of serum CRP following cinnamon supplementation. To our 257 
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knowledge, this is the first systematic review that has assessed the effects 258 
of cinnamon supplementation on serum CRP. 259 
Significant reductions in serum CRP levels by −0.81 mg/dL were 260 
observed following cinnamon supplementation with no detectable 261 
changes in the control group. These findings were consistent across four 262 
of the individual six RCTs assessed in this study18, 20-22. Reductions in the 263 
levels of serum CRP, as observed in the present study, are clinically 264 
important because levels <1 mg/dL are associated with a lower risk of 265 
cardiovascular events, with concentrations > 3 mg/dL exacerbating the 266 
risk of coronary heart disease up to 58%24, 25. 267 
There was significant heterogeneity between studies in this meta-analysis, 268 
and subgroup analysis indicated that cinnamon supplementation could 269 
lower the levels of serum CRP when the trial duration was >12 weeks. 270 
Evidence from other meta-analyses assessing the anti-inflammatory 271 
properties of complex medicinal herbs (cinnamon, ginger and other 272 
traditional herbs) have also demonstrated significant improvements in 273 
serum CRP levels with study durations exceeding 6 and 10 weeks26, 27.  274 
Subgroup analysis on studies with cinnamon doses of <1500 mg/day and 275 
≥1500 mg/day found significant reductions in the levels of serum CRP. It 276 
therefore seems likely that lower doses are effective and may be better 277 
than using larger doses of cinnamon, which have been associated with 278 
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certain adverse effects including diarrhea and headache 28. However, 279 
there were no reported adverse effects observed in the included studies in 280 
the present meta-analysis. Similar studies have also failed to report any 281 
adverse effect or reaction following cinnamon supplementation. Talaei et 282 
al. reported beneficial effects of 1000 mg/day cinnamon (Cinnamomum 283 
zeylanicum) without side effects 29, and Tjandrawinata et al. reported a 284 
lower risk of hypoglycemic episodes with no effect on gastrointestinal 285 
symptoms [27] 286 
Moreover, subgroup analysis based on baseline levels showed that 287 
cinnamon improved serum CRP levels in those with a higher baseline 288 
value (i.e. > 3 mg/dL), with heterogeneity decreasing significantly after 289 
subgroup analysis. This finding is in agreement with another studies in 290 
which vitamin E supplementation significantly reduced circulating levels 291 
of serum CRP only in those with a baseline value of > 3 mg/dL30.  292 
Therefore, the duration of the study and baseline serum CRP levels were 293 
considered to be important and potential sources of observed 294 
heterogeneity. 295 
CRP, and indeed hs-CRP, is one of the most common and frequently used 296 
biomarkers for inflammation status with predictive values for several 297 
chronic diseases including CVD 31-39. The anti-inflammatory properties of 298 
cinnamon has been reviewed extensively, and several mechanisms of 299 
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action have been described 40-44. In vitro and in vivo studies have reported 300 
inhibition of nuclear factor kappa B (NF-𝜅B) by 2`-301 
hydroxycinnamaldehyde isolated from C. cassia bark41, and tumor 302 
necrosis factor-𝛼 (TNF-α) with extracts of cinnamon in a 303 
lipopolysaccharide (LPS) model 42. Inhibition of TNF-α genes by 304 
cinnamon water extract via modulation of JNK, p38, ERK1/2 activation 305 
and Iκ-Bα degradation have also been demonstrated 43. Hong et al. 306 
reported the inhibition of the expression of TNF-α by polyphenol-rich 307 
cinnamon water extract (CWE) fraction containing procyanidins, 308 
catechin, epicatechin and ellagic acid 44. Cinnamon may also 309 
downregulate the expression of various NF-κB-regulated pro-310 
inflammatory adipo-cytokines, (i.e. MCP-1, MCP-4, and eotaxin and 311 
interleukins)45, 46, in addition to plasminogen activator inhibitor type-1 312 
(PAI-1), through the inhibition of the transcription factor early growth 313 
response (Egr)-1 gene product, which has been closely linked with insulin 314 
resistance and obesity47, 48.  315 
Some limitations of this meta-analysis include not controlling for 316 
confounding factors (i.e. dietary intake, physical activity and medications 317 
for several chronic conditions), which may have influenced our results. 318 
Most of the RCTs included were of a relatively small sample size, and the 319 
characteristics of the study population was heterogeneous (i.e. patients 320 
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with non-alcoholic fatty liver disease, T2DM, metabolic syndrome, 321 
obesity, pre-diabetes and rheumatoid arthritis). Despite these limitations, 322 
there were several strengths to this study. Firstly, it is to our knowledge, 323 
the first time a systematic review and meta-analysis has been performed 324 
in the evaluation of cinnamon supplementation on serum CRP levels. A 325 
random effects model was used for assessing heterogeneity between 326 
studies, and RCTs were assessed using subgroup analysis with performed 327 
sensitivity and meta-regression analyses.  328 
Conclusion 329 
In conclusion, the findings from this meta-analysis suggest some 330 
improvement in serum CRP levels following cinnamon supplementation, 331 
especially in patients with higher baseline CRP levels. However, due to 332 
the limited availability of RCTs further investigation is warranted. 333 
Acknowledgements 334 
We are grateful to our colleagues for their patience and their advice on 335 
searching the papers. 336 
Funding 337 
There is no funding sources in the writing of the manuscript, data 338 
collection, analysis, or interpretation; or the decision to submit it for 339 
publication. We have not been paid to write this article by a 340 
pharmaceutical company or other agency 341 
18 
 
 342 
Authors’ contributions 343 
N.V. and S.J. conceived and planned the experiments. S.J. and A.D. 344 
carried out the literature search in databases. S.J. and M.T. and A.D. 345 
contributed to quality assessment and statistical analysis. C.T. and N.V. 346 
contributed to the interpretation of the results. C.T. took the lead in 347 
writing the manuscript. All authors provided critical feedback and helped 348 
shape the research, analysis and manuscript. 349 
Conflict of interest  350 
There is no conflict of interest regarding this manuscript.  351 
 352 
 353 
354 
19 
 
References: 355 
1. Ravindran P, Babu N, Shylaja M. Cinnamon and Cassia The Genus Cinnamomum: 356 
Medicinal and Aromatic Plants–Industrial Profiles. Washington DC: CRC Press SGPT dan SGOT 357 
tikus putih J Gamma. 2004;1(1): 45-53. 358 
2. Ribeiro-Santos R, Andrade M, Madella D, et al. Revisiting an ancient spice with 359 
medicinal purposes: Cinnamon. Trends in Food Science & Technology. 2017;62: 154-169. 360 
3. Woehrlin F, Fry H, Abraham K, Preiss-Weigert A. Quantification of flavoring 361 
constituents in cinnamon: high variation of coumarin in cassia bark from the German retail 362 
market and in authentic samples from Indonesia. Journal of agricultural and food chemistry. 363 
2010;58(19): 10568-10575. 364 
4. Vallverdu-Queralt A, Regueiro J, Martinez-Huelamo M, Rinaldi Alvarenga JF, Leal LN, 365 
Lamuela-Raventos RM. A comprehensive study on the phenolic profile of widely used 366 
culinary herbs and spices: rosemary, thyme, oregano, cinnamon, cumin and bay. Food Chem. 367 
2014;154: 299-307. 368 
5. Chen L, Sun P, Wang T, et al. Diverse mechanisms of antidiabetic effects of the 369 
different procyanidin oligomer types of two different cinnamon species on db/db mice. 370 
Journal of agricultural and food chemistry. 2012;60(36): 9144-9150. 371 
6. Khan A, Safdar M, Khan MMA, Khattak KN, Anderson RA. Cinnamon improves 372 
glucose and lipids of people with type 2 diabetes. Diabetes care. 2003;26(12): 3215-3218. 373 
7. Anderson RA. Chromium and polyphenols from cinnamon improve insulin sensitivity: 374 
Plenary Lecture. Proceedings of the Nutrition Society. 2008;67(1): 48-53. 375 
8. Vallianou N, Evangelopoulos A, Kollas A, Kazazis C. Hypoglycemic and hypolipidemic 376 
effects of cinnamon2014. 377 
9. Zare R, Nadjarzadeh A, Zarshenas MM, Shams M, Heydari M. Efficacy of cinnamon in 378 
patients with type II diabetes mellitus: A randomized controlled clinical trial. Clinical 379 
Nutrition. 2018. 380 
10. Group MR, Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein 381 
and coronary heart disease in the MRFIT nested case-control study. American journal of 382 
epidemiology. 1996;144(6): 537-547. 383 
11. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute 384 
coronary syndromes. Journal of the American College of Cardiology. 2003;41(4): S37-S42. 385 
12. Cesari M, Penninx W, Newman A. Inflammatory markers and onset of cardiovascular 386 
events. ACC Current Journal Review. 2004;13(2): 10. 387 
13. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of 388 
cardiovascular events: results from the Health ABC study. Circulation. 2003;108(19): 2317-389 
2322. 390 
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic 391 
reviews and meta-analyses: the PRISMA statement. Annals of internal medicine. 392 
2009;151(4): 264-269, W264. 393 
15. Jafarnejad S, Tsang C, Taghizadeh M, Asemi Z, Keshavarz SA. A meta-analysis of 394 
cumin (Cuminum cyminim L.) consumption on metabolic and anthropometric indices in 395 
overweight and type 2 diabetics. Journal of Functional Foods. 2018;44: 313-321. 396 
16. Higgins J. Green S. Cochrane handbook for systematic reviews of interventions 397 
Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011. 398 
17. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, 399 
range, and the size of a sample. BMC Medical Research Methodology. 2005;5(1): 13. 400 
18. Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits 401 
on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in 402 
nonalcoholic fatty liver disease patients. Nutrition research. 2014;34(2): 143-148. 403 
20 
 
19. Azimi P, Ghiasvand R, Feizi A, Hariri M, Abbasi B. Effects of cinnamon, cardamom, 404 
saffron, and ginger consumption on markers of glycemic control, lipid profile, oxidative 405 
stress, and inflammation in type 2 diabetes patients. The review of diabetic studies: RDS. 406 
2014;11(3): 258. 407 
20. Jain SG, Puri S, Misra A, Gulati S, Mani K. Effect of oral cinnamon intervention on 408 
metabolic profile and body composition of Asian Indians with metabolic syndrome: a 409 
randomized double-blind control trial. Lipids in health and disease. 2017;16(1): 113. 410 
21. Liu Y, Cotillard A, Vatier C, et al. A dietary supplement containing cinnamon, 411 
chromium and carnosine decreases fasting plasma glucose and increases lean mass in 412 
overweight or obese pre-diabetic subjects: a randomized, placebo-controlled trial. PloS one. 413 
2015;10(9): e0138646. 414 
22. Shishehbor F, Rezaeyan Safar M, Rajaei E, Haghighizadeh MH. Cinnamon 415 
Consumption Improves Clinical Symptoms and Inflammatory Markers in Women With 416 
Rheumatoid Arthritis. Journal of the American College of Nutrition. 2018: 1-6. 417 
23. Soare A, Weiss EP, Holloszy JO, Fontana L. Multiple dietary supplements do not 418 
affect metabolic and cardiovascular health. Aging (Albany NY). 2014;6(2): 149. 419 
24. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to 420 
monomeric C-reactive protein on activated platelets localizes inflammation to 421 
atherosclerotic plaques. Circ Res. 2009;105(2): 128-137. 422 
25. Saboori S, Falahi E, Eslampour E, Zeinali Khosroshahi M, Yousefi Rad E. Effects of 423 
alpha-lipoic acid supplementation on C-reactive protein level: A systematic review and meta-424 
analysis of randomized controlled clinical trials. Nutrition, metabolism, and cardiovascular 425 
diseases : NMCD. 2018. 426 
26. Chung VC, Chen M, Ying Q, et al. Add-on effect of chinese herbal medicine on 427 
mortality in myocardial infarction: systematic review and meta-analysis of randomized 428 
controlled trials. Evidence-based complementary and alternative medicine : eCAM. 429 
2013;2013: 675906. 430 
27. Mazidi M, Gao H-K, Rezaie P, Ferns GA. The effect of ginger supplementation on 431 
serum C-reactive protein, lipid profile and glycaemia: a systematic review and meta-analysis. 432 
Food & Nutrition Research. 2016;60: 10.3402/fnr.v3460.32613. 433 
28. Wiweko B, Susanto CA. The Effect of Metformin and Cinnamon on Serum Anti-434 
Mullerian Hormone in Women Having PCOS: A Double-Blind, Randomized, Controlled Trial. 435 
Journal of Human Reproductive Sciences. 2017;10(1): 31-36. 436 
29. Talaei B, Amouzegar A, Sahranavard S, Hedayati M, Mirmiran P, Azizi F. Effects of 437 
Cinnamon Consumption on Glycemic Indicators, Advanced Glycation End Products, and 438 
Antioxidant Status in Type 2 Diabetic Patients. Nutrients. 2017;9(9): 991. 439 
30. Saboori S, Shab-Bidar S, Speakman JR, Yousefi Rad E, Djafarian K. Effect of vitamin E 440 
supplementation on serum C-reactive protein level: a meta-analysis of randomized 441 
controlled trials. European journal of clinical nutrition. 2015;69(8): 867-873. 442 
31. Black S, Kushner I, Samols D. C-reactive Protein. The Journal of biological chemistry. 443 
2004;279(47): 48487-48490. 444 
32. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to 445 
monomeric C-reactive protein on activated platelets localizes inflammation to 446 
atherosclerotic plaques. Circulation research. 2009;105(2): 128-137. 447 
33. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of 448 
inflammation in the prediction of cardiovascular disease in women. New England Journal of 449 
Medicine. 2000;342(12): 836-843. 450 
34. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the 451 
targeting of statin therapy in the primary prevention of acute coronary events. The New 452 
England journal of medicine. 2001;344(26): 1959-1965. 453 
21 
 
35. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of 454 
cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the 455 
Rural Health Promotion Project. Arteriosclerosis, thrombosis, and vascular biology. 456 
1997;17(6): 1121-1127. 457 
36. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of 458 
inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged 459 
men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular 460 
Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2): 237-242. 461 
37. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a 462 
comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard 463 
cholesterol screening as predictors of peripheral arterial disease. Jama. 2001;285(19): 2481-464 
2485. 465 
38. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart 466 
disease: prospective study and updated meta-analyses. Bmj. 2000;321(7255): 199-204. 467 
39. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, 468 
and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy 469 
American women. Circulation. 2003;107(3): 391-397. 470 
40. Lee SH, Lee SY, Son DJ, et al. Inhibitory effect of 2′-hydroxycinnamaldehyde on nitric 471 
oxide production through inhibition of NF-κB activation in RAW 264.7 cells. Biochemical 472 
pharmacology. 2005;69(5): 791-799. 473 
41. Muhammad JS, Zaidi SF, Shaharyar S, et al. Anti-inflammatory effect of 474 
cinnamaldehyde in Helicobacter pylori induced gastric inflammation. Biological and 475 
Pharmaceutical Bulletin. 2015;38(1): 109-115. 476 
42. Yu T, Lee S, Yang WS, et al. The ability of an ethanol extract of Cinnamomum cassia 477 
to inhibit Src and spleen tyrosine kinase activity contributes to its anti-inflammatory action. 478 
Journal of Ethnopharmacology. 2012;139(2): 566-573. 479 
43. Lee B-J, Kim Y-J, Cho D-H, Sohn N-W, Kang H. Immunomodulatory effect of water 480 
extract of cinnamon on anti-CD3-induced cytokine responses and p38, JNK, ERK1/2, and 481 
STAT4 activation. Immunopharmacology and immunotoxicology. 2011;33(4): 714-722. 482 
44. Hong J-W, Yang G-E, Kim YB, Eom SH, Lew J-H, Kang H. Anti-inflammatory activity of 483 
cinnamon water extract in vivo and in vitro LPS-induced models. BMC complementary and 484 
alternative medicine. 2012;12(1): 237. 485 
45. Shao-Ling W, Ying L, Ying W, et al. Curcumin, a potential inhibitor of up-regulation of 486 
TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK 487 
pathway. Biomedical and Environmental Sciences. 2009;22(1): 32-39. 488 
46. Woo H-M, Kang J-H, Kawada T, Yoo H, Sung M-K, Yu R. Active spice-derived 489 
components can inhibit inflammatory responses of adipose tissue in obesity by suppressing 490 
inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 491 
from adipocytes. Life sciences. 2007;80(10): 926-931. 492 
47. Pendurthi UR, Rao LVM. Suppression of transcription factor Egr-1 by curcumin. 493 
Thrombosis research. 2000;97(4): 179-189. 494 
48. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by 495 
curcumin and other nutraceuticals. Annual review of nutrition. 2010;30: 173-199. 496 
 497 
 498 
 499 
22 
 
 500 
Figure 1: Meta-analysis Flow Diagram 501 
 502 
Figure 2: Forest plots showing the pooled effect size of cinnamon supplementation on serum 503 
C-reactive protein (mg/L). Random effects model was used to pool the mean change of 504 
indicators. CI, confidence interval; I-squared inconsistency. 505 
 506 
Figure 3: Sensitivity analysis for the effect of cinnamon supplementation on serum CRP 507 
levels. 508 
 509 
Figure 4: Funnel plot of included studies measured serum CRP level. MD = Mean 510 
Difference, SE = standard error. 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
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Table 1: General characteristics of the included studies in the meta-analysis 520 
 521 
Auther Year Country Design 
No. of 
Subjects 
in case 
group 
No. of 
controls  
Gender 
Age(mean)- 
case group 
Age(mean)- 
control 
Inclusion criteria  
Clinical Condition 
of Subjects  
Follow-
up 
Duration 
(weeks) 
Dosage 
(mg/d) 
Co-Supplements or 
other drugs 
Significant Outcome 
Baseline CRP 
level  (mg/l) 
Askari  2014 Iran 
R, DB, 
PC 
23 22 F/M 44.8 ± 8.5 45.4 ± 8.2 
Age between 20 and 65 ;  
ALT not greater than 60 
U/L; no alcohol or drug 
abuse;no chemotherapy 
Nonalcoholic 
fatty liver 
disease 
(NAFLD) 
12 
         
1500  
No co-supplement 
FBS, HOMA index, 
QUICKI index, total 
cholesterol, triglycerides, 
ALT, AST, GGT and hs-
CRP changed significantly 
in the treatment group. 
5mg/l 
Azimi 2015 Iran 
R, SB, 
PC 
40 39 F/M 54.15± 1.0 53.64 ± 1.3 
Subjects with T2D, aged 
≥30 years, overweight, 
not on insulin therapy,  
not taking medications 
except for oral 
hypoglycemic agents. 
Type 2 diabetes 8 
         
3000 
Three glasses of 
black tea  
Significant reduction in total 
cholesterol, LDL, and 
elevation in HDL levels.                                      
5.74mg/l 
Jain 2017 India 
R, DB, 
PC 
58 58 F/M 44.3 ± 7.2 45.1 ± 8.4 
Subjects suffering from 
other chronic diseases 
(except for metabolic 
syndrome) or those on 
medication of lipid 
lowering drugs were 
excluded.                     
Metabolic 
syndrome 
16 
         
3000 
No co-supplement 
Significantly decrease in 
weight, WC, WHR, 
percentage body fat, total 
cholesterol, serum 
triglycerides, LDL-C, SBP, 
DBP and significant increase 
in HDL-C. 
2.8mg/l 
Liu 2015 France 
R, DB, 
PC 
26 26 F/M 
Not 
Mentioned 
Not 
Mentioned 
Subjects aged between 
25 and 65 years, 
overweight and 
unwilling to change their 
usual dietary and  
activity were included 
for randomization. 
Overweight or 
Obese Pre-
Diabetic 
16 456 
200 mg/day  L-
carnosine  
2.5 mg/day 
Chromium 
guanylate  
Insulin secretion, evaluated 
by HOMA-B%, increased 
significantly in supplement 
group. 
4mg/l 
Shishehbor 2018 Iran 
R, DB, 
PC 
18 18 F 44.66 ± 11.22 49.11 ± 7.45 
Having active 
Rheumatoid Arthritis, 
being under treatment 
with DMARDs,              
not receiving NSAIDs or 
cytokine inhibitors. 
Rheumatoid 
Arthritis 
8 2000 No co-supplement 
There was a significant 
decrease of serum levels of 
CRP and TNF-a in the 
cinnamon group. Diastolic 
blood pressure was also 
significantly lower in the 
intervention group. 
3.53mg/l 
Soare 2014 USA 
R, SB, 
PC 
28 26 F/M 47±5 44±6 
Participants were free of 
chronic disease. 
Exclusion criteria 
included chronic use of 
medications or dietary 
supplements, tobacco 
use, alcohol abuse, and 
habitual vigorous 
exercise. 
Healthy adults 24 1700 
100 mg of resveratrol, 
800 mg of green, 
black, and white tea, 
250 mg of 
pomegranate, 650 mg 
of quercetin, 500 mg 
of l carnitine, 600 mg 
of lipoic acid, 900 mg 
of curcumin, 1 g of 
sesamin and fish oil. 
No significant outcomes. 1.69mg/l 
24 
 
 522 
 523 
 524 
 525 
Table 2. Quality of bias assessment of the included trials according to the Cochrane guidelines. 526 
 527 
Studies ,Year Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete  
outcome 
data 
selective 
outcome 
reporting 
other 
potential 
sources 
of bias  
 
Askari;2014 L L L L L L U 
Azimi;2015 L L L H L L L 
Jain;2017 L U L H L L H 
Liu;2015 L U L H L L L 
Shishehbor;2018 L L L L L H U 
Soare;2014 L U H L L L L 
 528 
L, low risk of bias; H, high risk of bias; U, unclear risk of bias. 529 
 530 
 531 
 532 
 533 
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 534 
 Table 3: Subgroup analysis of cinnamon supplementation on serum CRP level 535 
 536 
Subgroup 
                    
  No   WMD (95% CI)   
Test for overall 
effect   
Test for 
heterogeneity   I2(%) 
Duration of 
study, weeks                     
  ≤12 weeks 3   -1.37 [-2.86, 0.12]   p=0.07   p<0.0001   91 
  >12 weeks 3   -0.42 [-0.65, -0.20]   P = 0.0002   P = 0.96   0 
Cinnamon 
dose, 
mg/day                      
  ≥1500 mg/d 4   -0.56 [-1.01, -0.10]   P = 0.02   P = 0.007   76 
  <1500 mg/d 2   -2.13 [-4.08, -0.19]   P = 0.03   P = 0.22   33 
CRP/hsCRP                     
  CRP 2   -0.96 [-2.14, 0.22]   P = 0.11   P = 0.003   89 
  hsCRP 4   -0.83 [-1.78, 0.11]   P = 0.08   P = 0.002   79 
Baseline 
CRP, mg/L 
                    
  <3 2   -1.26 [-2.62, 0.10]   P = 0.07   P < 0.0001   87 
  ≥3 4   -0.42 [-0.65, -0.20]   P = 0.0002   P = 0.77    0 
 537 
*: Abbreviations: CRP, C-reactive protein; hsCRP,  high-sensitivity C-reactive protein; WMD, weighted mean difference; CI, confidence interval. 538 
